David Bell

Dr. David Bell

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2017 in Journal of Materials Chemistry A
Verified
Journal Article
Closed access
PDF file
XWXiuxiu Wang
Xiuxiu Wang
BLBaoyu Li
Baoyu Li
DBDavid Bell
David Bell
Weifeng LiWeifeng Li
Weifeng Li
RZRuhong Zhou
Ruhong Zhou
Using molecular dynamics simulations, we investigate the performance of molybdenum disulfide nanotubes (MoS 2 NTs) as a medium for energy gas storage (hydrogen and methane).

11 April 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YSYi Song
Yi Song
DBDavid Bell
David Bell
RARizwan Ahmed
Rizwan Ahmed
KCKevin Chun Chan
Kevin Chun Chan
SLSangyun Lee
Sangyun Lee
RZRuhong Zhou
Ruhong Zhou
A previously reported autoreactive antigen, termed the X-idiotype, isolated from a unique cell population in Type 1 diabetes (T1D) patients, was found to stimulate their CD4+ T cells. This antigen was previously determined to bind more favorably than insulin and its mimic (insulin superagonist) to HLA-DQ8, supporting its strong role in CD4+ T cell activation. In this work, we probed HLA-X-idiotype-TCR binding and designed enhanced-reactive pHLA-TCR antigens using an in silico mutagenesis approach which we functionally validated by cell proliferation assays and flow cytometry. From a combination of single, double, and swap mutations, we identified antigen-binding sites p4 and p6 as potential mutation sites for HLA binding affinity enhancement. Site p6 is revealed to favor smaller but more hydrophobic residues than the native tyrosine, such as valine (Y6V) and isoleucine (Y6I), indicating a steric mechanism in binding affinity improvement. Meanwhile, site p4 methionine mutation to hydrophobic residues isoleucine (M4I) or leucine (M4L) modestly increases HLA binding affinity. Select p6 mutations to cysteine (Y6C) or isoleucine (Y6I) exhibit favorable TCR binding affinities, while a swap p5-p6 tyrosine–valine double mutant (V5Y_Y6V) and a p6-p7 glutamine–glutamine double mutant (Y6Q_Y7Q) exhibit enhanced HLA binding affinity but weakened TCR affinity. This work holds relevance to potential T1D antigen-based vaccine design and optimization.

21 April 2023 in Crystals
Verified
Journal Article
Open access
PDF file
JCJonah Cheung
Jonah Cheung
SWShagun Wazir
Shagun Wazir
DBDavid Bell
David Bell
JKJames N. Kochenderfer
James N. Kochenderfer
WHWayne A. Hendrickson
Wayne A. Hendrickson
PYPhilippe Youkharibache
Philippe Youkharibache
Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies are dependent upon designed transmembrane proteins to bind target antigens and stimulate an immune response. The success or failure of these CARs is only partially predictable, yet recent work has highlighted the importance of antigen binding scFvs driving distinct oligomerization states with varied CAR-T efficacy. Here, we sought to determine the extracellular structure of the anti-CD19 CAR 47G4-CD828Z. Unexpectedly, the resolved crystal structure revealed an IgVL homodimer bound along an inverted VL|VL interface. We found that the VL-VH linker, designed to be cleavage resistant, was cleaved, and the VH and CAR hinge domains were absent from the crystal structure lattice. Molecular Dynamics simulations revealed that the inverted VL|VL interface was more stable than the canonical VL|VL configuration. Our work substantiates the need to interrogate the scFv structure and CAR oligomerization state for optimal CAR-T design.

1 April 1999 in Journal of Hematotherapy
Verified
Journal Article
Closed access
DSDanna Skea
Danna Skea
NCNan-Hua Chang
Nan-Hua Chang
RHRobin Hedge
Robin Hedge
BDBarbara Dabek
Barbara Dabek
TWTruman Wong
Truman Wong
DBDavid Bell
David Bell
The use of human umbilical cord (UC) blood as a source of transplantable hematopoietic stem cells and progenitor cells may present some advantages over the use of BM. For example, it has been suggested that the degree of HLA matching may be less stringent, and the risk of GvHD may be lower. We have been studying the ex vivo expansion of UC blood T lymphocytes with a view to their use in the adoptive immunotherapy of cancer, autoimmunity, and infectious disease. We have developed a new method involving the use of a conditioned medium (XLCM TM) that consistently results in levels of UC blood T cell expansion not hitherto possible. Primary cultures of unfractionated low-density MNC (LDMNC) derived from UC blood treated with 5% XLCM TM routinely show expansions greater than 10,000-fold within 4 weeks. By contrast, similar FBS-free cultures treated with IL-2 expand less than 10-fold and not after 1 week, and cultures treated with IL-2 and concanavalin A (ConA) expand to a maximum of only 300-500-fold over 2 weeks and fail to continue to proliferate thereafter. The MAb, OKT3, which, when combined with IL-2 and FBS, is known to stimulate proliferation of adult peripheral blood lymphocytes, permitted only a 17-fold expansion of UC blood lymphocytes under the same conditions. Thus, XLCM TM, which can also stimulate adult peripheral blood lymphocyte expansion to levels exceeding 100,000-fold in 3-4 weeks, is uniquely able to stimulate proliferation of UC blood lymphocytes to high levels. From initiation of the UC blood or adult peripheral blood LDMNC/XLCM TM cultures up to approximately 2 weeks, the cultures are dominated by CD4+ T lymphocytes. By 4 weeks, >80% of the cultured cells bear the CD8+ phenotype, whereas UC blood T lymphocytes cultured in the presence of IL-2 are predominantly CD8+. Thus, XLCM TM not only allows high levels of expansion of UC blood T lymphocytes not heretofore possible but also permits the selective expansion of different T lymphocyte subsets from a single source.

17 November 2017 in Nanoscale
Verified
Journal Article
Closed access
PDF file
DBDavid Bell
David Bell
SKSeung-Gu Kang
Seung-Gu Kang
THTien Huynh
Tien Huynh
RZRuhong Zhou
Ruhong Zhou
Quantum dots (QDs) are being used increasingly in applications for solar panels, consumer electronics, and biomedical imaging. For biomedical applications, QDs are typically coated with a biocompatible molecule for the system of interest. Experiments have indicated a QD dose-dependent and surface coating-dependent toxicity, with a portion of the toxicity being ascribed to interference with biomolecules. In this work, the interaction of trioctylphosphine oxide (TOPO) coated (CdSe)13 QDs with the SRC homology 3 domain (SH3) protein domain are explored using molecular dynamics simulations. The results of this research agree well with experiments that show that at the lowest concentration, the QDs have little affinity for the native proline-rich motif (PRM) binding site of SH3. At higher concentrations, the QDs aggregate and increasingly prefer the PRM binding site, indicating that the normal SH3 function is impeded. This binding dependence is attributed to changes in the local density of the surface coated TOPO molecules upon aggregation. These results present possible interesting QD toxicity patterns and reveal the interdependence between dose and surface coating effects in QD toxicity.

1 February 2018 in Carbon
Verified
Journal Article
Closed access
DMDongfang Ma
Dongfang Ma
XMXuan-Yu Meng
Xuan-Yu Meng
DBDavid Bell
David Bell
SLShengtang Liu
Shengtang Liu
RZRuhong Zhou
Ruhong Zhou